Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.7% - Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) shares fell 3.7% during trading on Wednesday . The stock traded as low as $13.71 and last traded at $14.65. 1,371,627 shares were traded during mid-day trading, an increase of 16% from the average session volume of 1,180,047 shares. The stock had previously closed at $15.21.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Monday. They set a "sell" rating on the stock.

Tonix Pharmaceuticals Stock Performance

The stock has a market cap of $22.33 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm's 50 day moving average is $29.49 and its 200 day moving average is $25.62.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, beating the consensus estimate of ($203.00) by $180.00. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.